A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 in Normal Adult Volunteers

Trial Profile

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 in Normal Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2016

At a glance

  • Drugs ARC 520 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Sponsors Arrowhead Research Corporation
  • Most Recent Events

    • 01 Aug 2017 Results published in the Clinical Pharmacology in Drug Development
    • 09 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Oct 2014 Arrowhead escalated the dosage to 4 mg/kg, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top